From: Susan Guthrie
Sent: Tuesday, March 07, 2006 3:48 PM
Subject: New Drug is Promising Candidate for Treatment of Heart Failure - UA

Research Matters at the UA Sarver Heart Center

New Drug is Promising Candidate for Treatment of Heart Failure

 

March 7, 2006

From: Daniel Stolte, (520) 626-4083

                                                           

Researchers at the Sarver Heart Center at The University of Arizona in Tucson have identified a compound that might affect patients with heart failure. Unlike currently available drugs, the drug acts in two different ways to improve heart function while causing fewer side effects.

 

In heart failure, the performance of the heart muscle is impaired, compromising the heart’s ability to fully expand and contract. As a result, the heart is no longer able to adequately pump blood to meet the body’s needs.

 

The new compound, named DITPA (for Diiodothyropropionic acid), is chemically related to thyroid hormone, which is produced by the thyroid gland. Thyroid hormone is known to strengthen the heart’s ability to contract and relax, which results in improved heart performance. On the downside, thyroid hormone increases heart rate and stimulates appetite. Therefore, researchers have had a strong interest in developing thyroid hormone analogs with fewer undesirable side effects for the treatment of heart failure.

 

“The problem with most thyroid analogs is that they raise the heart rate as a side effect,” says Eugene Morkin, MD, co-director of the Sarver Heart Center and leading member of the team that developed DITPA. “DITPA improves the heart’s performance without making it beat faster. That’s what made it stand out to us.”

 

Dr. Morkin’s team isolated the new drug by screening 50 different thyroid analogs for their effects on heart function. DITPA is unique because it improves cardiac performance both during the contraction and the relaxation phase of the heart muscle. “DITPA helps the heart fill and empty more effectively,” says Morkin, who is a professor of medicine in the College of Medicine. “Both functions are important in fixing heart failure.”

 

Two clinical trials, each including 150 patients, are underway to investigate the efficacy and safety of the new drug.

 

Heart failure can result from coronary artery disease, as is the case in most adult patients, but it can also be caused by abnormalities in heart muscle structure or function (cardiomyopathies), some of which are genetic. Current pharmaceutical treatments usually entail a combination of drugs including diuretics, ACE-Inhibitors and beta-blockers.

 

# # #

 

 

Susan Guthrie
Associate Director, Public Affairs

University of Arizona, College of Medicine - Phoenix
4001 North Third Street, Suite 401
Phoenix, Arizona  85012
602-631-6555 (office) 480-241-7738 (cell)
sguthrie@email.arizona.edu

www.phoenix.arizona.edu

 

To read about the expansion of the UA College of Medicine in Phoenix go to http://www.phoenix.medicine.arizona.edu/About/News/Campus/